Open Access
Issue
Med Buccale Chir Buccale
Volume 19, Number 1, janvier 2013
Page(s) 21 - 31
Section Mises au point / Literature reviews
DOI https://doi.org/10.1051/mbcb/2012049
Published online 04 January 2013
  1. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012 May 16;5:CD003188. [Google Scholar]
  2. Diz P, Limeres J, Fedele S, Seoane J, Diniz M, Feijoo JF. Is oral bisphosphonate-related osteonecrosis of the jaw an endemic condition? Med Hypotheses 2012;78:315-8. [CrossRef] [PubMed] [Google Scholar]
  3. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTx testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410. [CrossRef] [PubMed] [Google Scholar]
  4. Veyrac G, Lebreton A, Jolliet P. Ostéonécroses de la mandibule et/ou du maxillaire associées à la prise de bisphosphonates. Lettre du Pharmacologue 2009;23:41-7. [Google Scholar]
  5. Guillaume B, Chappard D. Ostéonécrose de la mâchoire et chirurgie implantaire. Rapport et prévention thérapeutique. Chir Dent Fr 2008;78:45-52. [Google Scholar]
  6. Abi Najm S, Lysitsa S, Carrel JP, Lesclous P, Lombardi T, Samson J. Ostéonécrose des maxillaires chez des patients traités par bisphosphonates. Presse Med 2005;34:1073-7. [CrossRef] [PubMed] [Google Scholar]
  7. Salino S, Bodard AG, Timour Q. Ostéoradionécrose et ostéonécrose des maxillaires aux bisphosphonates. Encyc Med Chir Stomatol 28-865-A-10. Elsevier Masson SAS, Paris, 2010. [Google Scholar]
  8. Lesclous P, Abi Najm S, Samson J. Bisphosphonates et pratique bucco-dentaire. Rev Odont Stomat 2011;40:173-91. [Google Scholar]
  9. Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L, Blum C, Grötz KA, Wagner W. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 2010;6:11. [CrossRef] [PubMed] [Google Scholar]
  10. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-11. [CrossRef] [PubMed] [Google Scholar]
  11. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. [CrossRef] [PubMed] [Google Scholar]
  12. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238-9. [CrossRef] [Google Scholar]
  13. Pharma N. Zometa - Fachinformation des Arzneimittelkompendium Schweiz. In: Pharma N ed. Arzneimittelkompendium Schweiz. Documed AG, Basel, 2005. [Google Scholar]
  14. Pharma N. Aredia - Fachinformation des Arzneimittelkompendium Schweiz. In: Ag D ed. Arzneimittelkompendium Schweiz. Documed AG, Basel, 2005. [Google Scholar]
  15. Agence Nationale de Sécurité des Médicaments et des produits de santé (ANSM). Information de sécurité. Lettre aux professionnels de santé. Acide zolédronique/pamidronate de sodium et ostéonécrose de la mâchoire. 7 juillet 2005. Accessible le 26 septembre 2012 sur http://www.ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Acide-zoledronique-pamidronate-de-sodium-et-osteonecrose-de-la-machoire . [Google Scholar]
  16. Agence Nationale de Sécurité des Médicaments et des produits de santé (ANSM). Lettres aux professionnels de santé. Recommandations sur la prise en charge bucco-dentaire des patients traités par bisphosphonates. 18 décembre 2007. Accessible le 21 septembre 2012 sur http://www.ansm.sante.fr/content/download/11694/140950/version/2/file/lp071203.pdf [Google Scholar]
  17. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons (AAOMS) position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. J Oral Maxillofac Surg 2009;67 Suppl 1:2-12. [CrossRef] [Google Scholar]
  18. Abi Najm S, Lesclous P, Tommaso L, Bouzouita I, Carrel JP, Samson J. Ostéonécrose des maxillaires due aux bisphosphonates (2 e partie) : expérience genevoise. Med Buccale Chir Buccale 2008;14:63-84. [CrossRef] [EDP Sciences] [Google Scholar]
  19. Savoldelli C, Le Page F, Santini J, Scortecci G, Odin G. Ostéonécrose maxillaire sous bisphosphonates et implants dentaires. Rev Stomatol Chir Maxillofac 2007;108:555-8. [CrossRef] [PubMed] [Google Scholar]
  20. Meiller TF, Almubarak H, Weikel DS, Brahim J, Scheper MA. Bisphosphonate-associated osteonecrosis of the jaw: are we dealing with a localized non-traditional calciphylaxis ? Open Dent J 2012;6:5-7. [CrossRef] [PubMed] [Google Scholar]
  21. Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonates: the assessement, consent, and management, a proposed algorithm. Br Dent J 2009;206:93-8. [CrossRef] [PubMed] [Google Scholar]
  22. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15:613-20. [CrossRef] [PubMed] [Google Scholar]
  23. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induces exposed bone (osteonecrosis/osteoporosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75. [CrossRef] [PubMed] [Google Scholar]
  24. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-20. [CrossRef] [PubMed] [Google Scholar]
  25. Reskaa AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001;59:193-202. [PubMed] [Google Scholar]
  26. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl Med 2005;353:99-102. [CrossRef] [Google Scholar]
  27. Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 2011;77:b147. [PubMed] [Google Scholar]
  28. Vescovi P, Nammour S. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) therapy. A critical review. Minerva Stomatol 2010;59:183-203, 204-13. [Google Scholar]
  29. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos, E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risks factors. J Clin Oncol 2005;34:8580-7. [CrossRef] [PubMed] [Google Scholar]
  30. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71. [PubMed] [Google Scholar]
  31. Zervas K, Verrou E, Teleioudis Z, Vathsevanos K, Bouti A, Mihou D, Krikelis D, Terpos E. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single center experience in 303 patients. Br J Haematol 2006;134:620-3. [CrossRef] [PubMed] [Google Scholar]
  32. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann NY Acad Sci 2011;1218:47-54. [CrossRef] [Google Scholar]
  33. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007;65:1328-31. [CrossRef] [PubMed] [Google Scholar]
  34. Guarneri V, Donati S, Nicolini M, Giovanelli S, D’Amico R, Conte PF. Renal safety and efficacy of IV bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005;10:842-8. [CrossRef] [PubMed] [Google Scholar]
  35. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102 (Erratum in 2728). [CrossRef] [Google Scholar]
  36. Calvo-Villas JM, Tapia Torres M, Govantes Rodrigues J, Carreter de Granda E. Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid. Med Clin (Barc) 2006;127:576-9. [CrossRef] [PubMed] [Google Scholar]
  37. Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, Verri E, Franceschelli L, Goldhirsch A, Nole F. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006;17:1512-6. [CrossRef] [PubMed] [Google Scholar]
  38. Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L, D’Arco A, Ronconi S, Cellini C, Offidani M, Perrone G, Ceccolini M, Brioli A, Tura S, Baccarani M, Cavo M. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006;108:3951-2. [CrossRef] [PubMed] [Google Scholar]
  39. Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suarez MA, Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007;18:556-60. [CrossRef] [PubMed] [Google Scholar]
  40. Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaws in patients with multiple myeloma. Leukemia 2007;21:1545-8. [CrossRef] [PubMed] [Google Scholar]
  41. Garcia Saenz JA, Lopez Tarruella S, Garcia Paredes B, Rodriguez Lajusticia L, Villalobos L, Diaz Rubio E. Osteonecrosis of the jaws as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med Oral Patol Oral Cir Bucal 2007;12:e351-6. [PubMed] [Google Scholar]
  42. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23. [CrossRef] [PubMed] [Google Scholar]
  43. Ortega C, Montemurro F, Faggiuolo R, Vormola R, Nanni D, Goia F, Gillardino MO, Aglietta M. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol 2007;46:664-8. [CrossRef] [PubMed] [Google Scholar]
  44. Petrucci MT, Gallucci C, Agrillo A, Mustazza MC, Foa R. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica 2007;92:1289-90. [CrossRef] [PubMed] [Google Scholar]
  45. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Nat Cancer Inst 2007;99:1016-24. [CrossRef] [Google Scholar]
  46. Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinsert S, Solomayer EF, Wallwiener D, Krimmel M. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynaecological malignancies. Gynecol Oncol 2009;112:605-9. [CrossRef] [PubMed] [Google Scholar]
  47. Ibrahim T, Barbanti F, Giorgio-Marrano G, Mercatali L, Ronconi S, Vicini C, Amadori D. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. Oncologist 2008;13:330-6. [CrossRef] [PubMed] [Google Scholar]
  48. Walter C, Al-NAwas B, du Bois A, Buch L, Harter P, Grotz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009;115:1631-7. [CrossRef] [PubMed] [Google Scholar]
  49. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkei G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-69. [CrossRef] [PubMed] [Google Scholar]
  50. Nalliah R. Prevalence of bisphosphonate-related osteonecrosis in patients with cancer could be as high as 13,3 percent. J Am Dent Assoc 2012;143:170-1. [PubMed] [Google Scholar]
  51. Novartis Pharma S. Bisphosphonate und osteonekrosen des Kiefers. 2005. [Google Scholar]
  52. Dannemann K, Graätz KW, Zwahlen R. Clinical experience with bisphosphonate-induced osteochemonecrosis of the jaws. Swiss Med Wkly 2006;136:504-9. [PubMed] [Google Scholar]
  53. Silverman SL, Landsberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009;122:S33-45. [CrossRef] [Google Scholar]
  54. Walter C, Grötz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15:197-202. [CrossRef] [PubMed] [Google Scholar]
  55. Ripamonti CI, Maniezzo M, Camapa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137-45. [Google Scholar]
  56. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Mine Res 2008;23:826-36. [CrossRef] [PubMed] [Google Scholar]
  57. King AE, Umland EM. Osteonecrosis of the jaw in patient receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008;28:667-77. [CrossRef] [PubMed] [Google Scholar]
  58. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548-58. [CrossRef] [PubMed] [Google Scholar]
  59. Estillo CS, Van Poznak CH, Williams T, Evtimovska E, Tkach L, Halpern JL, Tunick SL. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study. J Clin Oncol 2004:22:8088. [Google Scholar]
  60. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risks factors. J Clin Oncol 2006;24:945-52. [CrossRef] [PubMed] [Google Scholar]
  61. Woeller A, Gering A, Brix M, Bettega G, Lebeau J. Ostéonécrose des maxillaires sous bisphosphonates : cinq cas. Rev Stomatol Chir Maxillofac 2006;107:417-22. [CrossRef] [PubMed] [Google Scholar]
  62. Pautke C, Kreutzer K, Weitz J, Knödler M, Münzel D, Wexel G, Otto S, Hapfelmeier A, Stürzenbaum S, Tischer T. Bisphosphonate related osteonecrosis of the jaw: a minipig large animal model. Bone 2012;51:592-9. [CrossRef] [PubMed] [Google Scholar]
  63. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007;4:42-55. [CrossRef] [PubMed] [Google Scholar]
  64. Hoff AO, Toth BB, Altundag K. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24:8528. [Google Scholar]
  65. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphposphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. [CrossRef] [PubMed] [Google Scholar]
  66. Bozas G, Roy A, Ramasamy V, Maraveyas A. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie 2010;33:321-3. [CrossRef] [PubMed] [Google Scholar]
  67. Jadu F, Lee L, Pharoah M, Reeve D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007;18:2015-19. [CrossRef] [PubMed] [Google Scholar]
  68. Scheper MA, BAdros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haemat 2009;22:S33-45. [Google Scholar]
  69. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S. Inhibition of oral mucosal cells wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839-47. [CrossRef] [PubMed] [Google Scholar]
  70. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Falsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society of bone and mineral research. J Bone Miner Res 2007;22:1479-91. [CrossRef] [PubMed] [Google Scholar]
  71. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57. [CrossRef] [PubMed] [Google Scholar]
  72. Stumpe MR, Chandra RK, Yunus F. Incidence and risk factors of bisphopsphonate-associated osteonecrosis of the jaws. Head Neck 2009;31:202-6. [CrossRef] [PubMed] [Google Scholar]
  73. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphophonates in multiple myeloma. Mayo Clin Proc 2006;81:1047-53. [CrossRef] [PubMed] [Google Scholar]
  74. Ruggiero SL, Woo SB. Bisphosphonate-related osteonecrosis of the jaws. Dent Clin North Am 2008;52:111-28. [CrossRef] [PubMed] [Google Scholar]
  75. Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology 2006;1:356-60. [CrossRef] [Google Scholar]
  76. Almasan HA, Baciut M, Rotaru H, Bran S, Almasan OA, Baciut G. Osteonecrosis of the jaws associated with the use of bisphosphonates!; Discussion over 52 cases. Rom J Morphol Embryol 2011;52:1233-41. [PubMed] [Google Scholar]
  77. American Dental Associsation (ADA). Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137:1144-50. [Google Scholar]
  78. Favus MJ. Diabetes and the risk of osteonecrosis of the jaw. J Clin Endocrinol Metab 2007;92:817-8. [CrossRef] [PubMed] [Google Scholar]
  79. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, Elad S. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrin Metab 2007;92:1172-5. [CrossRef] [Google Scholar]
  80. Magremanne M, Aubert C, Vervaet C, Dufrasne L, Evrard L, Daelemans P. Ostéochimionécrose maxillo-mandibulaire et bisphosphonates. A propos d’un cas et revue de la littérature. Rev Med Brux 2007;28:453-8. [Google Scholar]
  81. Robertson A, Kraenzlin ME, Zeilhofer HF, Meier C. Ostéonécrose maxillaire due aux bisphosphonates. Recommandations diagnostiques et thérapeutiques. Forum Med Suisse 2007;7:408-12. [Google Scholar]
  82. Miyazaki H, Nishimatsu H, Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Ishikawa A, Igawa Y, Hirano Y, Homma Y. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel. BJU Int. 2012 May 11. doi: 10.1111/j.1464-410X.2012.11205.x. [Google Scholar]
  83. Lazarovici TS, Yahalom R, Taicher S. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009;67:850-9. [CrossRef] [PubMed] [Google Scholar]
  84. Diel IJ, Fogelman I, Al-Nawas, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS. Pathophysiology, risk factors and management of bisphosphonates-associated osteonecrosis of the jaw: is there a diverse relationship of amino and non-aminobisphosphonate? Crit Rev Oncol Hematol 2007;64:186-93. [Google Scholar]
  85. Pires FR, Miranda A, Cardoso ES, Fregnani ER, Pereira CM, Correa ME, Almeida JP, Alves Fde A, Lopes MA, de Almeida OP. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 2005;63:1567-75. [Google Scholar]
  86. Rutkowski JL. Combined use of glucocorticoids and bisphosphonates may increase severity of bisphosphonate-related osteonecrosis of the jaw. J Oral Implantol 2011;37:505. [CrossRef] [PubMed] [Google Scholar]
  87. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93. [CrossRef] [PubMed] [Google Scholar]
  88. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008;66:223-30. [CrossRef] [PubMed] [Google Scholar]
  89. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parness H, Figg WD, Dahut WL. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009;27:221-6. [CrossRef] [PubMed] [Google Scholar]
  90. Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advances breast cancer. Breast Cancer Res Treat 2010;122:181-8. [CrossRef] [PubMed] [Google Scholar]
  91. Agence Nationale de Sécurité des Médicaments et des produits de santé (ANSM). Ostéonécrose de la mâchoire chez les patients atteints de cancers et traités par bevacizumab (Avastin®) ayant reçu précédemment ou de façon concomitante des bisphosphonates. 28 janvier 2011. Accessible le 21 septembre 2012 sur http://www.ansm.sante.fr/content/download/31026/409108/version/1/file/lp-110128-Avastin.pdf [Google Scholar]
  92. Agence Nationale de Sécurité des Médicaments et des produits de santé (ANSM). Ostéonécrose de la mâchoire chez les patients traités par sunitinib (Sutent®) et ayant reçu précédemment ou de façon concomitante des bisphosphonates. 30 décembre 2010. Accessible le 21 septembre 2012 sur http://www.ansm.sante.fr/content/download/30437/401660/version/1/file/lp-101230-Sunitinib.pdf [Google Scholar]
  93. Vieillard MH, Maes JM, Penel G, Facon T, Magro L, Bonneterre J, Cortet B. Thirteen cases of jaw osteonecrosis in patients on bisphosphonates therapy. Joint Bone Spine 2008;75:34-40. [CrossRef] [PubMed] [Google Scholar]
  94. La Ferla F, Paolicchi E, Crea F, Cei S, Graziani F, Gabriele M, Danesi R. An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related ostéonécroses of the jaw. Biomark Med 2012;6:201-9. [CrossRef] [PubMed] [Google Scholar]
  95. Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A, Zavras AI. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 2012;17:279-87. [CrossRef] [PubMed] [Google Scholar]
  96. Wessel JH, Dodson TB, Zavras A. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008;66:625-32. [CrossRef] [PubMed] [Google Scholar]
  97. Sambrook PN, Ebeling P. Osteonecrosis of the jaw. Curr Rheumatol Rep 2008;10:97-101. [CrossRef] [PubMed] [Google Scholar]
  98. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milan MA, Sanchis JM, Silvestre FJ, Scully C. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3. [CrossRef] [PubMed] [Google Scholar]
  99. Ruggiero SL, Gralow J, Marx R, Hoff AO, Schubert MM, Huryn J, Toth B, Damato K, Valero V. Practical guidelines for prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006;2:7-14. [CrossRef] [PubMed] [Google Scholar]
  100. Novartis. ONJ is uncommon, may be prevented, and can be managed. Accessible le 31 septembre 2012 sur http://www.zometa.com/pdf/Dental%20Health%20Kit%20Flash%20Card.pdf [Google Scholar]
  101. Khan AA, Sandor GK, Dore E. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-90. [CrossRef] [PubMed] [Google Scholar]
  102. Kühl S, Walter C, Acham S, Pfeffer R, Lambrecht JT. Bisphosphonate-related osteonecrosis of the jaws - A review. Oral Oncol 2012;48:938-47. [CrossRef] [PubMed] [Google Scholar]
  103. Brozoski MA, Traina AA, Zindel Deboni MC, Marques MM, Naclerio-Homem Mda G. Bisphosphonate-related osteonecrosis of the jaw. Rev Bras Reumatol 2012;52:230-70. [CrossRef] [PubMed] [Google Scholar]
  104. American Association of Oral and Maxillofacial Surgeons (AAOMS) position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76. [Google Scholar]
  105. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102. [CrossRef] [Google Scholar]
  106. Walter C, Al-NAwas B, Grötz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72. [CrossRef] [PubMed] [Google Scholar]
  107. Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, Brennan MT. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 2010;18:1099-106. [CrossRef] [PubMed] [Google Scholar]
  108. Erkan M, Bilgi O, Multluoglu M, Uzun G. Bisphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy. JOP. J Pancreas 2009;10:579-80. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.